IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
Melbourne (Australia) and Indianapolis (U.S.A.) – 20 October 2021. Telix presented the IPAX-1 study of TLX101 in glioblastoma at the Congress of Neurological Surgeons Annual Meeting
This article was updated on 5 November 2021 to include the IPAX-1 poster presentation.
Telix is pleased to announce the first set of peer-reviewed results from the IPAX-1 Ph I/II study of TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with external beam radiation therapy (XRT) in recurrent glioblastoma multiforme (GBM) has been delivered as a late-breaking oral presentation at the Congress of Neurological Surgeons (CNS) Annual Meeting currently taking place in Austin, Texas.
The data confirms the study has met its primary objective, demonstrating safety and tolerability of TLX101 at doses tested. The results also show overall survival (OS) of 15.97 months, to date, in the second line (recurrent) GBM setting. Six (6) out of 10 patients in the study are still alive and will be followed until 1 year after dosing for the final OS calculation (May 2022).
The primary objective of the study was to evaluate the safety and tolerability of intravenous 131I-IPA administered concurrently with second-line XRT in patients with recurrent GBM. Secondary objectives were to determine optimal dosing, biodistribution and radiation absorption into the tumour, as well as assess preliminary efficacy through clinical and imaging-based assessment of tumour response.
Based on these encouraging results, Telix confirms it intends to progress to a follow-on Phase II study and is currently finalizing the protocol in frontline post-surgery in combination with standard of care and using Telix’s TLX101-CDx (18F-FET) investigational agent as a companion diagnostic.
Safety Summary and Conclusions
All patients evaluated received similar total activity dose of ~2GBq (2000 MBq) of TLX101, either in a single administration or a triple-fractionated regime. The results demonstrated both dosing regimens, in combination with XRT, were well tolerated:
- The dosimetric analysis demonstrates that radiation exposure to key organs is well within prescribed safety limits.
- The most frequent treatment-emergent adverse event (TEAE) was fatigue, which occurred in three patients, followed by diarrhea, decreased lymphocyte count, headache, and cerebral oedema, all of which occurred in two patients.
- With the exception of cerebral oedema (swelling), a common side-effect of radiotherapy to the brain, adverse events typically had an intensity of grade 1 or grade 2. The therapy was generally well tolerated by patients.
Preliminary Overall Survival
- 10 patients have now completed therapy.
- Overall survival (OS) on this interim analysis shows median 15.97 months to date, with three patients exhibiting stable disease at day 135 and two with stable disease at day 180.
Figure 1: Overall survival (to date) indicates a median 15.97 months OS, with three patients exhibiting stable disease at day 135 and two with stable disease at day 180.
Dr. Colin Hayward, Chief Medical Officer at Telix said, “Whilst a single arm study, the overall survival demonstrated in this initial patient population is encouraging. GBM has a median survival from initial diagnosis of 12-15 months, so the prospect of potentially improved OS in the second line setting warrants further investigation in a larger patient cohort, including earlier stage patients.”
Dr. Josef Pichler, Kepler University Hospital, Austria, Principal Investigator in the study added, “These peer-reviewed data confirm that TLX101 in combination with XRT is safe and well-tolerated in patients with recurrent GBM, for whom there is an extremely poor prognosis and few treatment options. I look forward to evaluating this investigational asset in front-line therapy, to accelerate development in this underserved disease area with such high unmet medical need.”
Dr. Arthur Braat, PhD, MD from University Medical Centre, Utrecht, Netherlands said, “These peer-reviewed data confirm that TLX101 in combination with XRT is safe and well-tolerated in patients with recurrent GBM, for whom there is an extremely poor prognosis and few treatment options. I look forward to evaluating this investigational asset in front-line therapy, to accelerate development in this underserved disease area with such high unmet medical need.”
IPAX-1: PHASE 1/2 STUDY OF 4-L-[131I] IODO-PHENYLALANINE (131I-IPA) COMBINED WITH EXTERNAL RADIATION THERAPY (XRT) AS TREATMENT FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME
Authors: Josef Pichler1, Colin Hayward2, Mary Jessel2
1Kepler University Hospital, Linz, Austria; 2Telix Pharmaceuticals, Melbourne, Australia
To download the poster presentation please click here.
To read the full ASX announcement please click here.
To return to Telix’s homepage please click here.